Iron Metabolism Disturbance in a French Cohort of ALS Patients

Overview

Journal Biomed Res Int

Publisher Wiley

Specialties Biomedical Engineering
Biotechnology
General Medicine

Date 2014 Aug 8

PMID 25101285

Citations 30

Authors

Charlotte Veyrat-Durebex

Philippe Corcia

Aleksandra Mucha

Simon Benzimra

Cindy Mallet

Chantal Gendrot

Caroline Moreau

David Devos

Eric Piver

Jean-Christophe Pages

Francois Maillot

Christian R Andres

Patrick Vourch

Helene Blasco

Affiliations

Soon will be listed here.

Abstract

Objective: The aim of this study was to assess iron status in a cohort of amyotrophic lateral sclerosis (ALS) patients compared to controls in order to evaluate these parameters as a risk factor or a modifying factor of ALS.

Methods: We collected serum iron, ferritin, transferrin, total iron-binding capacity, and transferrin saturation coefficient (TSC) from 104 ALS patients at the time of diagnosis and from 145 controls. We reported phenotypic characteristics and evolution parameters such as ALSFRS-R and forced vital capacity at diagnosis and after one year of follow-up. In a first step we compared iron status between ALS patients and controls, and then we evaluated the relation between iron status and disease evolution of ALS patients using univariate and multivariate analysis.

Results: We observed increased concentrations of serum iron (P = 0.002) and ferritin (P < 0.0001) and increased TSC (P = 0.017) in ALS patients. We also showed an association between markers of iron status and high body weight loss in ALS patients. The multivariate analysis of survival highlighted a significant relation between ferritin level and disease duration (P = 0.038).

Conclusion: This is the first study showing a higher concentration of serum iron in ALS patients, strengthening the involvement of a deregulation of iron metabolism in ALS.

Citing Articles

Iron homeostasis and ferroptosis in muscle diseases and disorders: mechanisms and therapeutic prospects.

Ru Q, Li Y, Zhang X, Chen L, Wu Y, Min J Bone Res. 2025; 13(1):27.

PMID: 40000618 PMC: 11861620. DOI: 10.1038/s41413-024-00398-6.

Ferritin is closely associated with microglia in amyotrophic lateral sclerosis.

Gao J, Okolo O, Siedlak S, Friedland R, Wang X J Neuropathol Exp Neurol. 2024; 83(11):917-926.

PMID: 39001793 PMC: 11487107. DOI: 10.1093/jnen/nlae074.

Exploring antioxidant strategies in the pathogenesis of ALS.

Pinilla-Gonzalez V, Montecinos-Barrientos B, Martin-Kommer C, Chichiarelli S, Saso L, Rodrigo R Open Life Sci. 2024; 19(1):20220842.

PMID: 38585631 PMC: 10997151. DOI: 10.1515/biol-2022-0842.

HFE Mutations in Neurodegenerative Disease as a Model of Hormesis.

Marshall Moscon S, Connor J Int J Mol Sci. 2024; 25(6).

PMID: 38542306 PMC: 10970347. DOI: 10.3390/ijms25063334.

Research progress on ferroptosis in the pathogenesis and treatment of neurodegenerative diseases.

Wang L, Fang X, Ling B, Wang F, Xia Y, Zhang W Front Cell Neurosci. 2024; 18:1359453.

PMID: 38515787 PMC: 10955106. DOI: 10.3389/fncel.2024.1359453.

References

Nappi A, Vass E . Iron, metalloenzymes and cytotoxic reactions. Cell Mol Biol (Noisy-le-grand). 2000; 46(3):637-47. View

Winkler E, Sengillo J, Sagare A, Zhao Z, Ma Q, Zuniga E . Blood-spinal cord barrier disruption contributes to early motor-neuron degeneration in ALS-model mice. Proc Natl Acad Sci U S A. 2014; 111(11):E1035-42. PMC: 3964055. DOI: 10.1073/pnas.1401595111. View

van Rheenen W, Diekstra F, van Doormaal P, Seelen M, Kenna K, McLaughlin R . H63D polymorphism in HFE is not associated with amyotrophic lateral sclerosis. Neurobiol Aging. 2012; 34(5):1517.e5-7. DOI: 10.1016/j.neurobiolaging.2012.07.020. View

Shaw P . Molecular and cellular pathways of neurodegeneration in motor neurone disease. J Neurol Neurosurg Psychiatry. 2005; 76(8):1046-57. PMC: 1739758. DOI: 10.1136/jnnp.2004.048652. View

Hadzhieva M, Kirches E, Wilisch-Neumann A, Pachow D, Wallesch M, Schoenfeld P . Dysregulation of iron protein expression in the G93A model of amyotrophic lateral sclerosis. Neuroscience. 2012; 230:94-101. DOI: 10.1016/j.neuroscience.2012.11.021. View

Kimura F, Fujimura C, Ishida S, Nakajima H, Furutama D, Uehara H . Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS. Neurology. 2006; 66(2):265-7. DOI: 10.1212/01.wnl.0000194316.91908.8a. View

Brooks B, Miller R, Swash M, Munsat T . El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2001; 1(5):293-9. DOI: 10.1080/146608200300079536. View

Piskorz L, Lesiak T, Brocki M, Klimek-Piskorz E, Smigielski J, Misiak P . Biochemical and functional indices of malnutrition in patients with operable, non-microcelullar lung cancer. Nutr Hosp. 2011; 26(5):1025-32. DOI: 10.1590/S0212-16112011000500016. View

Pichler I, Del Greco M F, Gogele M, Lill C, Bertram L, Do C . Serum iron levels and the risk of Parkinson disease: a Mendelian randomization study. PLoS Med. 2013; 10(6):e1001462. PMC: 3672214. DOI: 10.1371/journal.pmed.1001462. View

10.

van Blitterswijk M, van Es M, Hennekam E, Dooijes D, van Rheenen W, Medic J . Evidence for an oligogenic basis of amyotrophic lateral sclerosis. Hum Mol Genet. 2012; 21(17):3776-84. DOI: 10.1093/hmg/dds199. View

11.

Marin B, Gil J, Preux P, Funalot B, Couratier P . Incidence of amyotrophic lateral sclerosis in the Limousin region of France, 1997-2007. Amyotroph Lateral Scler. 2009; 10(4):216-20. DOI: 10.1080/17482960902721626. View

12.

Goodall E, Greenway M, van Marion I, Carroll C, Hardiman O, Morrison K . Association of the H63D polymorphism in the hemochromatosis gene with sporadic ALS. Neurology. 2005; 65(6):934-7. DOI: 10.1212/01.wnl.0000176032.94434.d4. View

13.

Dixon S, Lemberg K, Lamprecht M, Skouta R, Zaitsev E, Gleason C . Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012; 149(5):1060-72. PMC: 3367386. DOI: 10.1016/j.cell.2012.03.042. View

14.

Kell D . Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson's, Huntington's, Alzheimer's, prions, bactericides, chemical toxicology and others as examples. Arch Toxicol. 2010; 84(11):825-89. PMC: 2988997. DOI: 10.1007/s00204-010-0577-x. View

15.

Jenner P . Clues to the mechanism underlying dopamine cell death in Parkinson's disease. J Neurol Neurosurg Psychiatry. 1989; Suppl:22-8. PMC: 1033306. DOI: 10.1136/jnnp.52.suppl.22. View

16.

Blasco H, Vourch P, Nadjar Y, Ribourtout B, Gordon P, Guettard Y . Association between divalent metal transport 1 encoding gene (SLC11A2) and disease duration in amyotrophic lateral sclerosis. J Neurol Sci. 2011; 303(1-2):124-7. DOI: 10.1016/j.jns.2010.12.018. View

17.

McCarthy R, Kosman D . Glial cell ceruloplasmin and hepcidin differentially regulate iron efflux from brain microvascular endothelial cells. PLoS One. 2014; 9(2):e89003. PMC: 3923066. DOI: 10.1371/journal.pone.0089003. View

18.

Qureshi M, Brown Jr R, Rogers J, Cudkowicz M . Serum ferritin and metal levels as risk factors for amyotrophic lateral sclerosis. Open Neurol J. 2009; 2:51-4. PMC: 2627516. DOI: 10.2174/1874205X00802010051. View

19.

Hardiman O . Management of respiratory symptoms in ALS. J Neurol. 2010; 258(3):359-65. DOI: 10.1007/s00415-010-5830-y. View

20.

Velasquez Rodriguez C, Parra Sosa B, Morales Mira G, Agudelo Ochoa G, Cardona Henao O, Bernal Parra C . ["Free" iron, transferrin and ferritin levels in serum and their relation with severe malnutrition]. An Pediatr (Barc). 2007; 66(1):17-23. DOI: 10.1157/13097353. View